The Success of Histamine-2 Receptor Antagonists

References

• Black J W, Duncan W AM, Durant C J, Ganellin C R, Parsons E M. Definition and antagonism of Histamine H2-receptors. Nature 1972; 236: 321–6
   Google Scholar
• Penston J G, Wormsley K G. Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3–29
   PubMed Web of Science ®Google Scholar
• Burland W L, Duncan W AM, Hesselbo T, et al. Pharmacological evaluation of cimetidine, a new histamine Hrrecep-tor antagonist, in healthy man. B J Clin Pharmacol 1975; 2: 481–6
   PubMed Web of Science ®Google Scholar
• Gudmand-Hoyer E, Birger Jensen K, Krag E, et al. Prophylactic effect of cimetidine in duodenal ulcer disease. Br Med J 1978; 1: 1095–7
   PubMed Web of Science ®Google Scholar
• Page M C, Lacey L A, Mills J G, Wood J R. Can higher doses of an H2-receptor antagonist accelerate ulcer healing?. Ailment Pharmacol Ther 1989; 3: 425–33
   PubMedGoogle Scholar
• Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 1990; 18: 302–8
   Google Scholar
• Bardhan K D, Bianchi-Porro G, Bose K, Daly M. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986; 8: 408–13
   PubMed Web of Science ®Google Scholar
• Jones D B, Howden C W, Burget D W, Kerr G D, Hunt R H. Acid suppression in duodenal ulcer; a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120–7
   PubMed Web of Science ®Google Scholar
• Thorat V K, Misra S P, Anand B S. Conventional versus On-Demand therapy for duodenal ulcer: results of a controlled therapeutic trial. Am J Gastroenterol 1990; 85: 243–8
   PubMed Web of Science ®Google Scholar
• Nwokolo C U, Gavey C J, Smith J TL, Pounder R E. The absorption of bismuth from oral doses of tripotassium dicitrato bis-muthate. Aliment Ther Pharmacol 1989; 3: 29–39
   PubMed Web of Science ®Google Scholar
• McLean A J, Harrison P M, Loannides-Demos L, Byrne A J, McCarthy P, Dudley F J. The choice of ulcer healing agent influences ulcer relapse rate and long term clinical outcome. Aust NZ J Med 1985; 15: 367–74
   PubMedGoogle Scholar
• Rauws E AJ, Tytgat G NJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233–5
   PubMed Web of Science ®Google Scholar
• George L L, Borody T J, Andrews P, et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust 1990; 153: 145–9
   PubMed Web of Science ®Google Scholar
• Axon A R. Duodenal ulcer: the villain unmasked?. Br Med J 1991; 302: 919–20
   PubMed Web of Science ®Google Scholar
• Gough K R., Bardhan F D, Crowe J P, Korman M G, Lee F I, Reed P I. Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre comparative trial. Lancet 1984; 2: 659–62
   PubMed Web of Science ®Google Scholar
• Alsted E M, Ryan F P, Holdsworth C D, Ashton M G, Moore M. Ranitidine in the prevention of gastric and duodenal ulcer relapse. Gut 1983; 24: 418–20
   PubMedGoogle Scholar
• Walan A, Bianchi-Porro G, Hentschel E, Bardhan K D, Delattre M. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397–405
   PubMed Web of Science ®Google Scholar
• Silvis S E. Final report on the United States multicentre trial comparing ranitidine to cimetidine as maintenance therapy following healing of duodenal ulcer. J Clin Gastroenterol 1985; 7: 482–7
   PubMed Web of Science ®Google Scholar
• Morris A I. Maintenance therapy for duodenal ulceration. Res Clin Forums 1988; 10: 33–8
   Google Scholar
• Penston J G, Wormsley K G. Long term maintenance treatment of gastric ulcers with ranitidine. Aliment Pharmacol Ther 1990; 4: 339–55
   PubMedGoogle Scholar
• Penston J G, Wormsley K G. Efficacy and safety of long term maintenance therapy of duodenal ulcers. Scand J Gastroenterol 1989; 24: 1145–52
   PubMed Web of Science ®Google Scholar
• Nwokolo C U, Smith J TL, Gavey C, Sawyerr A, Pounder R E. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4: 29–45, Suppl 1
   PubMed Web of Science ®Google Scholar
• Lee F I, Hardman M, Jaderberg M E. Maintenance treatment of duodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers. Gut 1991; 32: 151–3
   PubMedGoogle Scholar
• Kurata J H, Koch G G, Nogawa A N. Comparison of ranitidine and cimetidine ulcer maintenance. J Clin Gastroenterol 1987; 9: 644–50
   PubMed Web of Science ®Google Scholar
• Robinson M G, Griffin J W, Bowers J, Warner C W. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti inflammatory drugs. Dig Dis Sci 1989; 34: 424–8
   PubMed Web of Science ®Google Scholar
• Lancaster-Smith M J, Jaderberg M E, Jackson D A. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32: 252–5
   PubMed Web of Science ®Google Scholar
• Johnson N J, Boyd E JS, Mills J G, Wood J R. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300mg q.d.s. Aliment Pharmacol Ther 1989; 3: 259–66
   PubMed Web of Science ®Google Scholar
• Jones R H. Community prevalence and clinical impact: symposium on managing life with acid reflux disease Athens. 1992
   Google Scholar
• Richardson C T, Peters M N, Feldman R N, et al. Treatment of Zollinger-ellison syndrome with exploratory laparotomy, proximal gastric vagotomy and H,-receptor antagonists. Gastroenterology 1985; 89: 357–67
   PubMed Web of Science ®Google Scholar
• Zentler-Munro P L, Fine D R, Batten J C, Northfield T C. Effect of cimetidine on enzyme activation, bile acid precipitation and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985; 26: 892–901
   PubMedGoogle Scholar
• Cortot A, Flemming C R, Malagelada J-R. Improved nutrient absorption after cimetidine in short bowel syndrome with gastric hypersecretion. N Engl J Med 1979; 300: 79–80
   PubMed Web of Science ®Google Scholar
• Marchant J, Summers K, McLsaac R L, Wood J R. A comparison of two ranitidine intravenous infusion regimens in critically ill patients. Aliment Pharmacol Ther 1988; 2: 55–63
   PubMedGoogle Scholar
• Tordoff S G, Sweeney B P. Acid aspiration prophylaxis in 288 obstetric anaesthetic departments in the United Kingdom. Anaesthesia 1990; 45: 776–80
   PubMedGoogle Scholar
• Walt R P, Cottrell J, Mann S G, Freemantle N P, Langman M JS. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340: 1058–62
   PubMed Web of Science ®Google Scholar
• Collins R, Langman M. Treatment with histamine H,-antag-onists in acute upper gastrointestinal haemorrhage. Implications of randomized trials. N Engl J Med 1985; 313: 660–6
   PubMed Web of Science ®Google Scholar
• Gotthard R, Bodemar G, Brodin U, Jonsson K A. Treatment with cimetidine, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7–18
   PubMed Web of Science ®Google Scholar
• Colin-Jones D G, Langman M JS, Lawson D H, Vessey M P. Postmarketing surveillance of the safety of cimetidine: mortality during the second, third and fourth years of follow up. Br Med J 1985; 291: 1084–8
   PubMedGoogle Scholar